Bookmark
Forward
QuickView for Encainide (compound)
PubChem
| Name: | Encainide |
|---|---|
| PubChem Compound ID: | 48033 |
| Description: | One of the ANTI-ARRHYTHMIA AGENTS, it blocks SODIUM CHANNELS and slows conduction within the His-Purkinje system and myocardium. |
| Molecular formula: | C22H28N2O2 |
| Molecular weight: | 352.47 g/mol |
| Synonyms: |
BENZAMIDE, 4-METHOXY-N-(2-(2-(1-METHYL-2-PIPERIDINYL)ETHYL)PHENYL)-, (+-)-; BRN 0497572; Encainide; Encainidum [Latin]; 66778-36-7; Enkaid; Encainida [Spanish]; (+-)-4-Methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide; 5-22-09-00511 (Beilstein Handbook Reference); Encainide [French].
show more » |
DrugBank
Identification
| Name: | Encainide |
|---|---|
| Name (isomeric): | DB01228 |
| Drug Type: | small molecule |
| Description: | One of the ANTI-ARRHYTHMIA AGENTS, it blocks SODIUM CHANNELS and slows conduction within the His-Purkinje system and myocardium. |
| Synonyms: |
Encainidum [Latin]; Encainida [Spanish]; Encainide [French]
|
| Brand: | Enkaid |
| Category: | Antiarrhythmic Agents, Sodium channel blockers, Anti-Arrhythmia Agents |
| CAS number: | 66778-36-7 |
Pharmacology
| Indication: | Encainide is a class Ic antiarrhythmic agent which was used for management of irregular heartbeats, such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation. |
|---|---|
| Pharmacology: |
Used to treat irregular heartbeats, encainide decreases excitability, conduction velocity, and automaticity as a result of slowed atrial, atrioventricular (AV) nodal, His-Purkinje, and intraventricular conduction. It causes a slight but significant prolongation of refractory periods in these tissues. The greatest effect is on the His-Purkinje syste...
show more » |
| Mechanism of Action: | Encainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. |
| Route of elimination: | A radiolabeled dose of encainide is excreted in approximately equal amounts in the urine and feces. |
| Half Life: | 1-2 hours |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
Enzymes
